FOLH1 and prostate carcinoma: In contrast, 177Lu-PSMA-617 demonstrates selective and sustained uptake in PSMA-expressing prostate cancer cells, including those within bone lesions, as confirmed by autoradiographic and immunohistochemical analyses.